Annovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BERWYN, Pa., Jan. 31, 2020 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE American: ANVS), a clinical stage, drug platform company […]